E.g., 04/02/2020
E.g., 04/02/2020

bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

First of 3 diagnostic tests for  SARS-CoV-2 coronavirus available from bioMérieux

11 March, 2020

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

14 January, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.

World Antibiotic Awareness Week, 18-24 November, 2019

18 November, 2019

The 2019 edition of World Antibiotic Awareness Week (WAAW) will take place from November 18th – 24th. This annual campaign, organized by the World Health Organization (WHO), aims to increase awareness of drug-resistant infections  and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.

World Sepsis Day 2019

13 September, 2019

Webinar (hosted by CIDRAP): Value of Diagnostics to Enhance Antimicrobial Stewardship

16 May, 2019

CIDRAP-ASP WEBINAR NOW AVAILABLE ON-LINE

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”

15 May, 2019

“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients

15 April, 2019

Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury

19 March, 2019

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

Pioneering diagnostics